



**Agenda subject to change prior to August 22 meeting.**

**Prescription Drug Affordability Board Meeting Agenda**

**Friday, August 22, 2025 from 10:00 am - 2:00 pm**

Zoom Meeting Information:

[https://us06web.zoom.us/join/ztZAlcuytrDljGdaPynbWag\\_zQyK5tmEwERUa#/registration](https://us06web.zoom.us/join/ztZAlcuytrDljGdaPynbWag_zQyK5tmEwERUa#/registration)

**Call to Order, Roll Call, & Minutes Approval**

**10:00 - 10:05 am**

**Board Member & Director Updates**

**10:05 - 10:10 am**

**Rulemaking Hearing**

**10:10 am - 12:30 pm\***

*Prescription Drug Affordability Board Rule 3 CCR 702-9: Part 4.3: Upper Payment Limit for Enbrel*

- *Rule Introduction*
- *Enbrel Data Presentation from Staff*
  - *Executive Session: The Board may meet in Executive Session to discuss confidential, trade-secret, or proprietary information pursuant to sections 24-6-402(3)(a)(III), C.R.S., and 10-16-1404(3), C.R.S.*
- *Board Deliberation*
- *Witness Testimony*
  - *Witness testimony will be limited to three minutes per person. Board members may ask questions of witnesses, and the time limit does not apply to answering questions from the Board.*

**Break**

**12:30 - 12:40 pm**

**Board Business**

**12:40 - 2:00 pm**

- *APCD Data Validation - Cosentyx Validated Data Addendum*
- *UPL Implementation*
- *Stakeholder Workgroup Update*
- *2026 PDAB Meeting Schedule*
- *Presentation on Stelara Biosimilars from PORTAL*
- *APCD Data Validation - Stelara Validated Data Addendum*

**\* Please note:** *The rulemaking hearing for Enbrel UPL may run longer than the time allotted on the agenda. Due to the number of agenda items and the rulemaking hearing, a general public comment session has not been scheduled for this meeting. Stakeholders who wish to submit comments or additional written testimony to the Board can email [dora\\_ins\\_pdab@state.co.us](mailto:dora_ins_pdab@state.co.us).*



**COLORADO**

**Prescription Drug  
Affordability Board**

Division of Insurance

**Agenda subject to change prior to August 22 meeting.**

*The Board may meet in Executive Session to discuss confidential, trade-secret, or proprietary information pursuant to sections 24-6-402(3)(a)(III), C.R.S., and 10-16-1404(3), C.R.S.*

*The Board may meet in Executive Session to receive legal advice pursuant to section 24-6-402(3)(a)(II), C.R.S.*

*If you are in need of an accommodation to access PDAB meetings or materials, please notify staff at [dora\\_ins\\_pdab@state.co.us](mailto:dora_ins_pdab@state.co.us).*

*Councilmembers of the Prescription Drug Affordability Advisory Council may attend the August 22, 2025, Prescription Drug Affordability Board Meeting and may participate in the meeting, which may include providing public comment.*